-
5 highlights of the national talk preliminary examination list! PD-1 opened a "roll" of large
Time of Update: 2022-09-14
Then in the upcoming 2022 medical insurance negotiations, even if the PD-1 of multinational pharmaceutical companies does not appear in the preliminary review list, the "four little dragons" are not only facing competition with each other, but also to join several newly approved PD-(L)1, what kind of price will be refreshed this year, it is worth looking forward to.
-
ASCO's 5-year survival rate for specific lung cancer patients is 43%. PD-L...
Time of Update: 2021-06-12
On June 5th, AstraZeneca announced that its blockbuster PD-L1 inhibitor Imfinzi (durvalumab) has shown significant results in a phase 3 clinical trial for the treatment of stage III non-small cell lung cancer (NSCLC) Long-term efficacy.
-
ASCO's 5-year survival rate for specific lung cancer patients is 43%. The long-term efficacy of PD-L1 therapy is significant
Time of Update: 2021-06-10
On June 5th, AstraZeneca announced that its blockbuster PD-L1 inhibitor Imfinzi (durvalumab) has shown significant performance in a phase 3 clinical trial for the treatment of stage III non-small cell lung cancer (NSCLC) Long-term efficacy.
-
Lung cancer is overweight! Mercadon Keytruda first-line treatment of PD-L1 high expression lung
Time of Update: 2020-10-06
September 22, 2020 // -- Merck Co) recently presented five-year survival data for the first-line treatment of non-small cell lung cancer (NSCLC) in the key Phase III KEYNOTE-024 trial of the anti-PD-1 therapy Keytruda (Korida, generic name: pembrolizumab, Pabli pearl monoantigen) at the 2020 Virtual Conference of the European Society of Medical Oncology (ESMO).
-
Go on sale for 5 years! Market trend forecast of PD - (L) 1 monoclonal antibody in 2019
Time of Update: 2019-08-07
Five years since its launch, Pd - (L) 1 monoclonal antibody has become the most successful innovative drug, which has refreshed the clinical treatment schemes of non-small cell lung cancer, three nega